Prognostic value of anti-gp210 antibodies in primary biliary cholangitis: A Systematic review and meta-analysis.

What was studied

This review pooled studies on anti-gp210 antibodies in primary biliary cholangitis, or PBC. PBC is a long-term liver disease. The team searched several databases up to January 2025. 12 records were included. They compared patients with the antibody to patients without it.

What they found

People with the antibody had more liver failure. The relative risk was 6.11. Death was also more common, with a relative risk of 1.92. The response rate to ursodeoxycholic acid was lower, with a relative risk of 0.81. The antibody was also independently linked to a poor outlook. The hazard ratio was 4.53. Blood levels of GGT, IgM and IgG were higher. Albumin was lower.

What it means for patients

The authors say PBC patients with the antibody have a worse outlook. They say adding the antibody test to care could improve risk sorting. They say it could also guide personal care.

Why it is not certain yet

A review can only be as good as the studies in it. The abstract does not rate the quality of the studies. The link shows who may fare worse, not that the antibody causes it. The abstract gives no detail on how long patients were followed.

Source

Prognostic value of anti-gp210 antibodies in primary biliary cholangitis: A Systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.